region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 7.

33. The T cell activating bispecific antigen binding molecule according to any one of the preceding claims, wherein the target cell antigen is CD20 and the Fab molecule which specifically binds to the target cell antigen comprises a heavy chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 30 and a light chain variable region comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 31.

34. Use of the T cell activating bispecific antigen binding molecule of any one of claims 1 to 33 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.

35. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 33 in a pharmaceutically acceptable form.

36. A method for inducing lysis of a target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of claims 1-33 in the presence of a T cell.